In re Neurontin Antitrust Litigation, No. 02-1390; U.S. District Court (DNJ); opinion by Hochberg, U.S.D.J.; filed August 10, 2011. DDS No. 59-7-3406 [14 pp.]
Before the court is the class plaintiffs’ motion for discovery pursuant to the crime-fraud exception to the attorney-client privilege. Plaintiffs seek an in camera review of documents deemed privileged by defendants Pfizer Inc. and Warner-Lambert Company (collectively, Pfizer) in order to determine whether the crime-fraud exception applies.
